Second Quarter Highlights: — Achieved revenue of $113.0 million in the second quarter of 2025 versus $98.0 million in the second quarter of 2024, an increase of 15% on a GAAP basis and 14% on a non-GAAP constant currency basis — Net income was $1.3 million, or $0.03 per fully diluted share and non-GAAP net […]
(NASDAQ:AVPT), Total quarterly revenue surpassed $100 million for the first timeSecond quarter SaaS revenue of $77.3 million, representing 44% year-over-year growth, 40% on a constant currency basisSecond quarter Total revenue of $102.0 million, representing 31% year-over-year growth, 27% on a constant currency basisTotal ARR of $367.6 million, representing 27% year-over-year growth JERSEY CITY, N.J., Aug.
(NASDAQ:REAL), Q2 2025 Revenue of $165 million, up 14% Year-Over-YearQ2 2025 Net Loss of $(11) million improved $5 million Year-Over-YearQ2 2025 Adjusted EBITDA of $6.8 million improved $8.6 million Year-Over-YearRecord high quarterly Gross Merchandise Value and Total Revenue SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) — The RealReal, Inc. (Nasdaq: REAL)–the world's largest online marketplace
— Reported sales increased 3.9%; organic sales increased 2.8% — Increases full year organic sales growth outlook to +2.0% to +3.0% — Increases full year earnings per share outlook to $5.80 to $5.95 Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2025. https://mma.prnewswire.com/media/2369614/Solventum_Logo.jpg Second Quarter 2025 Highlights — Sales
(NASDAQ:APYX), CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) — Apyx Medical Corporation, an advanced energy technology company and manufacturer of Renuvion(R) and the newly launched AYON Body Contouring System(TM), today announced the strategic appointments of two accomplished sales executives to its leadership team. These additions support the Company's continued global expansion and the commercial launch
(NASDAQ:SGHT), MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2025, and raised its
(NasdaqGM:ETNB), – ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – ENTRUST Phase 3 topline data in severe hypertriglyceridemia (SHTG) expected in 1Q 2026 – – Cash, cash equivalents, and marketable
(NASDAQ:FDUS), Board of Directors Declared Total Dividends of $0.57 per Share for Third Quarter 2025 Base Dividend of $0.43 and Supplemental Dividend of $0.14 Per Share EVANSTON, Ill., Aug. 07, 2025 (GLOBE NEWSWIRE) — Fidus Investment Corporation (NASDAQ:FDUS) (“Fidus” or the “Company”), a provider of customized debt and equity financing solutions, primarily to lower middle-market
(NASDAQ:MDGL), CONSHOHOCKEN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 1, 2025 to 26 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The
(NASDAQ:PCT), ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) — PureCycle Technologies, Inc. (Nasdaq: PCT), a U.S.-based company revolutionizing plastic recycling, announced today a corporate update for the second quarter ending June 30, 2025. Management Commentary PureCycle CEO Dustin Olson commented, “We have begun to implement our growth plans following our successful $300 million capital raise